Clinical trials are critical for developing new treatments, but the industry faces chronic delays. Around 70% of trials are delayed before they even begin, and nearly 60% face costly amendments along the way. For big pharma running hundreds of trials a year, the financial stakes are enormous. But the real cost is human – every delay slows down access to treatments that could save lives.